Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease
- 1 January 2015
- journal article
- review article
- Published by Elsevier in Autoimmunity Reviews
- Vol. 14 (1) , 1-9
Abstract
No abstract availableKeywords
This publication has 106 references indexed in Scilit:
- Long‐Term Safety and Efficacy of Rilonacept in Patients With Systemic Juvenile Idiopathic ArthritisArthritis & Rheumatism, 2013
- Inflammasome and cytokine blocking strategies in autoinflammatory disordersClinical Immunology, 2013
- Cellular and Humoral Mechanisms Involved in the Control of TuberculosisJournal of Immunology Research, 2012
- A multicentre, randomised, double-blind, placebo-controlled trial with the interleukin-1 receptor antagonist anakinra in patients with systemic-onset juvenile idiopathic arthritis (ANAJIS trial)Annals of the Rheumatic Diseases, 2011
- Interleukin-1 in the pathogenesis and treatment of inflammatory diseasesBlood, 2011
- Genome-wide association study identifies variants in the MHC class I, IL10, and IL23R-IL12RB2 regions associated with Behçet's diseaseNature Genetics, 2010
- Anakinra in the treatment of polyarticular-course juvenile rheumatoid arthritis: safety and preliminary efficacy results of a randomized multicenter studyClinical Rheumatology, 2008
- A pilot study to evaluate the safety and efficacy of the long‐acting interleukin‐1 inhibitor rilonacept (interleukin‐1 trap) in patients with familial cold autoinflammatory syndromeArthritis & Rheumatism, 2008
- Neurological symptoms of Adamantiades-Behcet's syndromeJournal of Neurology, Neurosurgery & Psychiatry, 2006
- Long‐term safety and maintenance of clinical improvement following treatment with anakinra (recombinant human interleukin‐1 receptor antagonist) in patients with rheumatoid arthritis: Extension phase of a randomized, double‐blind, placebo‐controlled trialArthritis & Rheumatism, 2002